Meeting
2023 ASCO Annual Meeting
A phase I trial of palbociclib (palbo) and bosutinib (bos) with fulvestrant (fulv) in patients (pts) with hormone receptor–positive, HER2-negative (HR+/HER2-) metastatic breast cancer (MBC) refractory to an aromatase inhibitor (AI) and a CDK4/6 inhibitor (CDK4/6i).
Authors
Candace Bavette Mainor
Medstar Georgetown University Hospital-Lombardi Comprehensive Cancer Center, Washington, DC
Candace Bavette Mainor , Elizabeth Dominic Barrows , Hongkun Wang , Filipa Lynce , Nadia Ashai , Julie Marie Collins , Nicole Swanson , Julie Castle , Antonella Novielli , Joyce Slingerland , Claudine Isaacs , Paula R Pohlmann
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Clinical Trial Registration Number
NCT 03854903
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 1079)
DOI
10.1200/JCO.2023.41.16_suppl.1079
Abstract #
1079
Poster Bd #
300
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Long-term safety of inavolisib (GDC-0077) in an ongoing phase 1/1b study evaluating monotherapy and in combination (combo) with palbociclib and/or endocrine therapy in patients (pts) with PIK3CA-mutated, hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (BC).
First Author: Philippe L. Bedard
Poster
2021 ASCO Annual Meeting
Phase I safety and efficacy study of autophagy inhibition with hydroxychloroquine to augment the antiproliferative and biological effects of preoperative palbociclib plus letrozole for estrogen receptor-positive, HER2-negative metastatic breast cancer (MBC).
First Author: Akshara Singareeka Raghavendra
Poster
2019 ASCO Annual Meeting
A real-world evidence study of CDK4/6 inhibitor treatment patterns and outcomes in metastatic breast cancer by gBRCA mutation status.
First Author: Kimmie McLaurin
Poster
2019 ASCO Annual Meeting
Lasofoxifene as a potential treatment for ER+ metastatic breast cancer.
First Author: Muriel Laine